

Reference number(s)
1912-A, 1913-A

## SPECIALTY GUIDELINE MANAGEMENT

**CETROTIDE (cetorelix acetate)**  
**FYREMADEL (ganirelix acetate)**  
**GANIRELIX (branded generic)**  
**cetorelix acetate**  
**ganirelix acetate**

### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### FDA-Approved Indications

Cetrotide, Fyremadel, cetorelix, and ganirelix are indicated for the inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation.

All other indications are considered experimental/investigational and not medically necessary.

#### II. MEDICAL BENEFIT ALIGNMENT

Specialty Guideline Management coverage review will be bypassed for drug(s) being requested for a procedure that has been approved under a member's medical benefit plan. Such members will be exempt from the requirements in Sections III. A medical authorization number and confirmation of the approved procedure(s) will be required.

***NOTE: Some plans may opt-out of medical benefit alignment. Members receiving coverage under such plans must meet the requirements in Sections III.***

#### III. CRITERIA FOR INITIAL APPROVAL

##### **Inhibition of premature luteinizing hormone (LH) surges**

Authorization of 12 months may be granted for the inhibition of premature LH surges in members undergoing ovulation induction or assisted reproductive technology (ART).

#### IV. CONTINUATION OF THERAPY

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

#### V. REFERENCES

1. Cetrotide [package insert]. Rockland, MA: EMD Serono; December 2023.

Reference number(s)
1912-A, 1913-A

2. Fyremadel [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc.; October 2023.
3. Ganirelix [package insert]. Jersey City, NJ: Organon USA LLC; February 2024.
4. Cetrorelix [package insert]. Parsippany, NJ: Teva Pharmaceuticals; March 2024.
5. Bakas P, Konidaris S, Liapis A, et al. Role of gonadotropin-releasing hormone antagonist in the management of subfertile couples with intrauterine insemination and controlled ovarian stimulation. *Fertil Steril*. 2011;95:2024-2028.